Navigation Links
Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
Date:11/15/2010

harmaceuticals Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, double-blind study conducted in 29 patients with Type II diabetes assessed the safety of ORMD-0801 in patients with Type II diabetes. Results were presented by the company's Chief Scientific Officer, Dr. Miriam Kidron, at the Tenth Annual Meeting of the Diabetes Technology Society, in Bethesda, Maryland.

The poster presentation entitled "Extended exposure to an oral insulin formulation yields decreased insulin secretion in Type II diabetes subjects," described Oramed's first extended exposure study to its oral insulin product (ORMD-0801), where 21 patients were treated with ORMD-0801, self-administered daily for a period of six weeks. In parallel, a group of eight patients received placebo capsules administered under the same treatment regimen. ORMD-0801 proved safe and tolerable, with no reports of serious adverse events throughout the study. In addition, no cumulative effects of extended ORMD-0801 exposure were noted, and only two mild cases of transient hypoglycemia were reported. Treatment efficacy was evaluated via markers quantified from blood samples drawn at the start and end of the study. Daily administration of oral insulin led to a statistically significant decrease in both insulin and C-reactive protein (CRP) levels, in contrast to their elevation among placebo-treated individuals. Moreover, the percentage of subjects demonstrating clinically relevant reductions in insulin, c-peptide, fasting blood glucose (FBG) and Hb1Ac levels was consistently higher in the ORMD-0801 cohort, when compared to its placebo counterpart. This study addressing, for the first time, potential long-term safety concerns from extended ORMD-0801 administrations, demonstrated safety and no seri
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010
2. Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism
3. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
4. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
5. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
6. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
7. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
8. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
9. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
10. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
11. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... 31, 2014 2014 Market ... a professional and in-depth research report on ... Polyacrylamide information, including Polyacrylamide definition, classification, application, ... industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment ...
(Date:8/30/2014)... The Global and China Electrical ... study on the current state of the Electrical ... The report provides a basic overview of the ... Global market analysis and Chinese domestic market analysis ... trends and competitive landscape of the market. A ...
(Date:8/29/2014)... based on electrons, but one of the most promising ... circuits based on light (photons) instead of electrons. First, ... stream of single photons and control their direction. Researchers ... to achieve this control, but now scientists at the ... stream of photons emitted one at a time and ...
(Date:8/29/2014)... According to a new market report published by Transparency ... valued at USD 3,754.6 million in 2012 and is estimated ... CAGR of 5.9% from 2013 to 2019. , Nearly half ... by bone and joint disorders, and this number is expected ... will continue to increase the demand for orthobiologics. Other factors ...
Breaking Biology Technology:International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... of Multi-Use Clearance for Axxent(R), System ... Radiation Therapy, SUNNYVALE, Calif., May 21 ... from the U.S. Food & Drug Administration,(FDA) for ... System for the treatment of endometrial cancer. Previously,cleared ...
... Co., Ltd. announced today,that it has entered into an ... a German biotechnology company focusing on research into,antibodies for ... 100 percent of the stock and make a,one-time payment ... Closure of the transaction is subject to clearance under ...
... world converge on Regenesis, SCOTTSDALE, Ariz., May ... that markets the Provant(R) Wound Therapy,System, announced today ... purpose is to guide advanced scientific investigations into ... and further,application of Regenesis, platform technology to clinical ...
Cached Biology Technology:FDA Clears New Applicators for Endometrial Cancer Treatment With Xoft's Axxent(R) Electronic Brachytherapy System 2FDA Clears New Applicators for Endometrial Cancer Treatment With Xoft's Axxent(R) Electronic Brachytherapy System 3FDA Clears New Applicators for Endometrial Cancer Treatment With Xoft's Axxent(R) Electronic Brachytherapy System 4Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 2Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 3Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 2Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 3
(Date:9/2/2014)... in Taiyuan, China, have substantially improved the health of ... reduction in costs associated with loss of life and ... the Columbia Center for Children,s Environmental Health (CCCEH) at ... University, the Center of Diseases Control and Prevention of ... Health. , The study is the first to document ...
(Date:9/2/2014)... of lithographic limestone is well known as a ... that area (for example, Archaeopteryx). Now, for the ... the French equivalent of these outcrops - discoveries ... known water treader. , Despite the abundance of ... have been obtained from the Late Kimmeridgian equivalents ...
(Date:9/2/2014)... done in by it. New research at Rockefeller University ... gap in mice with very similar genetic backgrounds ... the development of psychiatric disorders such as anxiety and ... as it goes through its life. And we suspect ... genes, and as a result, affect an animal,s susceptibility ...
Breaking Biology News(10 mins):Clean air halves health costs in Chinese city 2Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... Cheryl Hayashi, a biologist at UC Riverside and a national ... a $500,000 MacArthur Fellowship, one of the most prestigious awards ... MacArthur Fellows for 2007 named by the John D. and ... award, the MacArthur Fellowship is a no strings attached grant ...
... help policy makers to estimate the consequences of various ... much toll must be charged for the desired policy ... all travellers or maximising the toll incomes (revenues). Based ... the impacts on road congestion and the total toll ...
... antimicrobials bind and thereby get inactivated in the mucus ... may have found a way to help cystic fibrosis ... this work has potential as a therapeutic strategy against ... professor of materials science and engineering, of physics, and ...
Cached Biology News:UC Riverside biologist receives prestigious MacArthur Fellowship 2UC Riverside biologist receives prestigious MacArthur Fellowship 3Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials 2
...
... Ferrofluid products perform optimally when ... Systems MagCellect Magnet. To accommodate ... iron boron permanent magnet holds ... mm test tubes or two ...
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Biology Products: